Merck Kgaa's Acquisition of Bio-techne Makes Strategic Sense
Dow Jones
Jun 26
1622 GMT - Merck KGaA's deal to buy Bio-Techne makes sense from a strategic rationale perspective, with the German company upgrading its life-science portfolio, Bernstein says in a research note. Bernstein says the valuation on the U.S. life-sciences tools supplier looks expensive but notes that the market appears to like the deal, with Merck's shares gaining after the news. The price tag also raises the question of whether the sector sees life sciences tools as a winner in the AI space, according to Bernstein. "We expect this deal to go through with no hitches," Bernstein says. Merck shares closed 4.9% higher at 147 euros. (sarah.sloat@wsj.com)
(END) Dow Jones Newswires
June 25, 2026 12:22 ET (16:22 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.